###### Significance Statement

To our knowledge, this is the first randomized sham-controlled clinical trial of a 4-week course of transcranial random noise stimulation (tRNS) for the treatment of depression. tRNS is a relatively novel form of noninvasive electrical stimulation that uses mild, randomly fluctuating currents to constrain homeostatic mechanisms and increase brain excitability. We investigated effects across multiple validated mood outcomes and comprehensively assessed cognitive, neurophysiological, and physical side effects to examine the safety of tRNS. We found no differences between active and sham conditions for all mood outcomes and are thus unable to lend support for tRNS as an effective treatment for depression. We found tRNS to be well tolerated with no adverse acute cognitive, neuropsychological, or severe physical side effects, suggesting a course of 20 repeated sessions can be delivered safely.

Introduction {#s1}
============

Although there are a number of established treatments for depression, a sizeable proportion of patients still fail to adequately respond, with a conservative estimate of approximately one-third of these not reaching remission even after 4 trials of different antidepressant medication classes ([@CIT0066]). In addition, many patients fail to complete a course of antidepressants due to side effects ([@CIT0065]; [@CIT0077]). While electroconvulsive therapy (ECT) remains the most effective treatment, with response rates of up to 70% ([@CIT0030]), treatment uptake and adherence can be limited by patient concerns over possible cognitive side effects and the need for general anesthetic. Thus, there has been interest in the development of novel, nonconvulsive brain stimulation techniques that are well tolerated and have a benign side effect profile, such as transcranial electrical stimulation. These neuromodulatory techniques could have the greatest potential for translation into widespread clinical use, being relatively inexpensive, easy to use, portable, and safe ([@CIT0005]; [@CIT0050]). Here we report an investigation of the efficacy of one such technique, transcranial random noise stimulation (tRNS), for the treatment of depression.

Transcranial electrical stimulation involves applying a weak electrical current to cerebral tissue via scalp electrodes, resulting in modulation of neuronal membrane potentials and spontaneous firing rates ([@CIT0051]) that can lead to long-term changes in cortical excitability and plasticity ([@CIT0052]; [@CIT0060]). Applying a direct current between the electrodes, referred to as transcranial direct current stimulation (tDCS), has been demonstrated to have antidepressant effects in clinical trials ([@CIT0039]; [@CIT0009]; [@CIT0012]). Recent meta-analyses of randomized, sham-controlled trials have found tDCS to be more effective than sham stimulation, with significantly higher remission and response rates as well as a greater reduction in depressive symptoms ([@CIT0011]; [@CIT0049]). As depression has increasingly been conceptualized as a disorder underpinned by disrupted neuroplasticity ([@CIT0057]; [@CIT0037]), cumulative changes to synaptic functioning may underlie the therapeutic effects observed in clinical trials of tDCS ([@CIT0075]). Modifying stimulation parameters to enhance cortical excitability effects may therefore present a pathway to increase treatment efficacy.

tRNS is a more recently developed transcranial electrical stimulation technique that involves randomly fluctuating current intensities over a broad frequency spectrum (between 0.1 and 640 Hz). There is some evidence that tRNS has comparable, if not greater, cortical excitatory effects compared with tDCS ([@CIT0045]; [@CIT0032]; [@CIT0033]). A single session of 10 minutes of 1 mA tRNS to the motor cortex has been found to produce a greater increase in cortical excitability than tDCS, lasting up to 60 minutes beyond the stimulation period ([@CIT0045]; [@CIT0033]), although tDCS may lead to a longer period of excitation of at least 90 minutes poststimulation ([@CIT0045]). tRNS may also be applied with a direct current offset so that the stimulation incorporates neuromodulatory features of tDCS in addition to limiting homeostatic responses via randomly fluctuating current intensities. Results from [@CIT0032] suggest that tRNS with a direct current offset may be more effective in increasing motor cortical excitability than the more common application of tRNS without an offset.

There has been a burgeoning growth in recent years of studies investigating the application of tRNS to enhance sensory processing ([@CIT0025]; [@CIT0063]; [@CIT0016]), motor performance ([@CIT0001]; [@CIT0034]), and cognition ([@CIT0074]; [@CIT0061]; [@CIT0041]; [@CIT0071]; [@CIT0078]) in healthy participants with largely promising results. To date, however, few studies have examined the effectiveness of tRNS for clinical/therapeutic uses, with such studies typically characterized by small sample sizes and/or varying efficacy ([@CIT0015]; [@CIT0029]; [@CIT0055]; [@CIT0031]; [@CIT0035]; [@CIT0067]). Regarding the effects of tRNS on mood, there is currently only 1 report involving treatment of major depressive disorder (MDD). [@CIT0015] reported a case of a patient diagnosed with MDD who had responded to 2 trials of tDCS (2 mA, 20 minutes, 15 sessions over 3 weeks) prior to trialing a 4-week course of open-label tRNS (2-mA range with 1-mA direct current offset, 20 sessions lasting 20 minutes each). It was found that by the 15th session, there was a 63% reduction from baseline in the severity of depressive symptoms compared with a reduction of 31% and 25% at the end of the acute treatment phase in the 2 prior trials of tDCS. For all 3 trials, depression scores at baseline were similar, but the patient reported faster improvement with tRNS and lesser skin sensations compared with tDCS. Given this encouraging case report finding and the potential theoretical advantages of tRNS relative to tDCS, further investigation of the antidepressant effects of tRNS is warranted.

The primary aim of this study, therefore, was to conduct the first randomized, sham-controlled trial of tRNS in depression. It was hypothesized that tRNS would have significant antidepressant efficacy compared with a sham control over a 4-week treatment phase. A secondary aim of this study was to examine whether antidepressant effects of tRNS were mediated by restoration of brain neuroplasticity. We hypothesized that antidepressant response to tRNS would be associated with increased brain plasticity given prior findings of reduced neuroplasticity in depressed individuals compared with healthy matched controls ([@CIT0059]) and findings suggesting a normalization of neuroplasticity following antidepressant treatment using tDCS ([@CIT0060]). Lastly, as this is the first treatment trial of tRNS for depression, a comprehensive neuropsychological test battery was designed specifically to be sensitive to symptom changes, measure any adverse cognitive effects, and assess any potential acute cognitive-enhancing effects.

Materials and Methods {#s2}
=====================

Trial Design {#s3}
------------

The main study phase used a double-blinded, parallel, randomized, sham-controlled design. Participants were assigned by a computer-generated random number sequence to 1 of 2 groups: active tRNS or sham tRNS. Randomization was stratified according to whether participants were diagnosed with unipolar or bipolar depression. Participants were required to attend a total of 20 tRNS sessions over 4 weeks conducted on consecutive weekdays during the sham-controlled phase. Participants who missed 5 or more sessions during the sham-controlled phase were withdrawn from the trial and were excluded from analyses using a per-protocol approach. All participants were offered an additional 20 sessions of open-label active tRNS over 4 weeks, also administered every weekday. After treatment in the acute daily treatment phases, participants entered a taper phase during which they received once-weekly tRNS treatment for 4 weeks with the final taper session coinciding with a 1-month follow-up visit. Participants were then followed-up at 3, 6, and 9 months. Participants and raters were blinded to tRNS condition, and blinding was maintained until the study was completed and the dataset locked.

Mood, neuroplasticity, and neuropsychological function were assessed at the intervals shown in [supplementary Table 1](#sup1){ref-type="supplementary-material"}. Adequacy of blinding to treatment was assessed at the end of the sham-controlled phase by asking participants and raters to guess the tRNS condition administered during the first 4 weeks of treatment. To investigate whether treatment expectations may be a predictor of response, participants completed the Treatment Expectancy Questionnaire (see [supplementary Figure 1](#sup1){ref-type="supplementary-material"}) at baseline before the first tRNS session.

The study was powered for the primary aim of testing efficacy over the sham-controlled phase. From pilot data, it was assumed that tRNS would be at least as effective as tDCS when tested in a sham-controlled trial given that sampling criteria were very similar. Means and SDs of the active and sham treatment groups from our previous, sham-controlled, 3-week trial of tDCS ([@CIT0039]) were used, with outcomes extrapolated for a 4-week comparison period. This resulted in an effect size of Cohen's *d* = 0.7. For 80% power and α = .05, a sample of 33 participants per group was required to demonstrate a difference between active and sham treatment.

Participants {#s4}
------------

At study entry, participants were at least 18 years old; in a current major depressive episode (as part of a MDD or bipolar disorder) of a minimum 4 weeks duration, defined according to Diagnostic and Statistical Manual of Mental Disorders (4th edition, text revision; DSM-IV-TR) criteria and established using the Mini International Neuropsychiatric Interview (Version 5.0.0) ([@CIT0072]) and study clinician assessment; and had a total score of at least 20 on the Montgomery-Asberg Depression Rating Scale (MADRS) ([@CIT0047]). Participants were free of antidepressant medications or continued on stable doses of antidepressant medications to which they had failed to respond after an adequate course of treatment, with dosage unchanged for at least 4 weeks prior to study entry. Bipolar participants were required to be on a mood stabilizer medication (e.g., lithium, valproate, or carbamazepine) as prophylaxis against treatment-emergent mania or hypomania for the duration of the study.

Exclusion criteria included psychotic disorder as per Diagnostic and Statistical Manual of Mental Disorders (4th edition, text revision), drug or alcohol abuse or dependence within 12 months of study entry, inadequate response to ECT in the current depressive episode, current benzodiazepine medication, rapid clinical response required (e.g., due to high suicide risk), clinically defined neurological disorder or insult, metal in the cranium, skull defects, skin lesions on the scalp at electrode sites, or pregnancy.

The study was approved by the human research ethics committee of the University of New South Wales and was conducted at the Black Dog Institute in Sydney, Australia. Participants provided written informed consent for this study. Recruitment began in January 2013 and the last follow-up was conducted in 2017. The study was registered with the ClinicalTrials.gov website (identifier: NCT01792414).

Transcranial Random Noise Stimulation {#s5}
-------------------------------------

A DC-Stimulator Plus device (NeuroConn GmbH, Germany) applied high-frequency tRNS (100--640 Hz) via 2 7 × 5 cm saline-soaked sponge-covered electrodes held in position by a headband. Active tRNS was administered for 30 minutes per session with a range of 2 mA and an offset of 2 mA. The anode was placed over F3 (as per the 10--20 international electroencephalogram system), corresponding to the left dorsolateral prefrontal cortex, and the cathode over F8. For sham stimulation, the current was ramped up over 10 seconds, left on for 30 seconds, then gradually ramped down over 10 seconds, so that both treatment groups experienced an initial tingling sensation. The tRNS machine was then left on until the end of the session to preserve blinding. This sham procedure resulted in adequate blinding for tDCS in previous trials (e.g., [@CIT0038], [@CIT0039]) and was therefore expected to be sufficient for tRNS, which produces milder skin sensations compared with tDCS ([@CIT0002]). Participants were comfortably seated at rest and did not engage in any particular tasks during stimulation.

Clinical Outcome Measures {#s6}
-------------------------

The primary outcome measure for comparing active and sham tRNS was the MADRS, which was administered by trained raters with established inter-rater reliability (intraclass correlation coefficient \> 0.7). Secondary measures were the Clinician Global Impression---Improvement ([@CIT0028]), Beck Depression Inventory ([@CIT0003]), and Quality of Life Enjoyment and Satisfaction Questionnaire---Short Form ([@CIT0021]) scales.

Neuroplasticity Outcome Measures {#s7}
--------------------------------

As an optional study offered to participants in the main tRNS trial, a paired associative stimulation (PAS) paradigm previously described in [@CIT0058] was used to assess the effects of tRNS on neuroplasticity. The PAS testing was conducted at baseline before the first tRNS session and again after completion of the sham-controlled and open-label phases. Briefly, the PAS paradigm involves measuring motor evoked potentials following single-pulse transcranial magnetic stimulation via electromyography before and after applying a stimulation protocol (i.e., PAS) to the motor cortex to assess changes in motor cortical excitability (see the Supplementary Material for a detailed description of PAS methodology).

Neuropsychological Outcome Measures {#s8}
-----------------------------------

The following neuropsychological battery was administered to comprehensively assess cognitive function: California Verbal Learning Test-II ([@CIT0018])---verbal learning and memory; Ruff 2 & 7 ([@CIT0064])---attention processes; Wechsler Adult Intelligence Scale-IV edition Digit Span subtest ([@CIT0082])---simple auditory attention and working memory; Symbol Digit Modality Test ([@CIT0073])---psychomotor processing speed; Delis-Kaplan Executive Function System Verbal Fluency test ([@CIT0019])---phonemic fluency, semantic fluency, cognitive flexibility; and Cognitive Failures Questionnaire ([@CIT0007])---subjective cognitive functioning. Alternative versions of the California Verbal Learning Test-II, Delis-Kaplan Executive Function System Verbal Fluency, and Symbol Digit Modality Test were used to minimize practice effects. In addition, computer administered cognitive tests were used to assess safety and acute effects. A simple reaction time test, in which participants were instructed to press a space bar as soon as they saw a cross appear in the middle of a computer screen, was administered immediately before and after the first tRNS session. An emotion recognition task ([@CIT0046]), which assessed recognition of 6 basic facial emotions, was also administered after the first tRNS session.

Physical Adverse Events {#s9}
-----------------------

As an additional safety outcome measure, physical adverse events were assessed each session using a tRNS Side Effects Questionnaire ([supplementary Figure 2](#sup1){ref-type="supplementary-material"}), adapted from [@CIT0008], which collected information regarding the type of adverse event, its severity, and its causality.

Statistical Analyses {#s10}
--------------------

All statistical analyses were conducted using SPSS software (IBM SPSS Statistics 25 for Windows; SPSS Inc.). Outcome measures were analyzed for change over the sham-controlled phase using a mixed-effects repeated measures (MERM) model with a restricted number of covariates. Time was entered as a repeated-measures factor with an unstructured covariance matrix, tRNS condition (active or sham) was a between- participants factor, and participants were included as a random effect. For mood and quality-of-life outcomes, covariates were selected based on prior reports of their significant effect on antidepressant response to transcranial electrical stimulation; these included treatment resistance ([@CIT0005]) (assessed by the Maudsley Staging Method; [@CIT0022]) and presence of concurrent antidepressant medications (e.g., selective-serotonin reuptake inhibitors, serotonin--norepinephrine reuptake inhibitors; [@CIT0009], [@CIT0010]). A MERM model was similarly used for neuropsychological outcomes, with MADRS mood scores at the respective time points included as a covariate. Acute cognitive effects following the first session were examined using a 2-way repeated-measure ANOVA, with factors of tRNS condition and time (pre and post session 1). For the emotion recognition task, a multivariate ANOVA was conducted with the between- participant factor of tRNS condition.

Additional MERM analyses were conducted for the primary outcome measure (MADRS). Baseline scores on the Treatment Expectancy Questionnaire were added as a covariate to the MERM analysis to test whether treatment expectations modified mood outcomes. To assess whether medication use affected outcomes, each medication class (antidepressants, benzodiazepines, antipsychotics, lithium, and anticonvulsants) was entered as the only covariate in separate MERM analyses.

The number of responders (defined as a reduction in MADRS total score of ≥50% from baseline) and remitters (defined as a final MADRS total score \<10) at the end of the sham-controlled phase were compared between active and sham tRNS groups using a Fisher's exact test.

The association between participant or rater guesses (active or sham) and the participant's assigned tRNS condition (active or sham) was tested using a Pearson chi-square test with Yates' continuity correction. Cohen's kappa statistic was used to assess agreement between participant and rater guesses.

Statistical tests were 2-tailed and significance was set at *P* \< .05.

Results {#s11}
=======

A total of 69 participants met inclusion criteria and were randomized to receive either active or sham tRNS during the sham-controlled phase (see the CONSORT flow diagram, [supplementary Figure 3](#sup1){ref-type="supplementary-material"}). A total of 66 participants (sham: 34, active: 32) completed the sham-controlled phase and were analyzed using a per-protocol approach. [Table 1](#T1){ref-type="table"} shows demographic and clinical characteristics for active and sham tRNS groups at baseline.

###### 

Comparison of demographic and clinical characteristics at baseline

                                                  Sham          Active
  ----------------------------------------------- ------------- -------------
  n                                               34            32
  Medications (yes/no)                                          
   Any concurrent medication                      27/7          22/10
   Antidepressant                                 23/11         20/12
   Lithium                                        1/33          2/30
   Benzodiazepine^*a*^                            2/32          2/30
   Antipsychotic                                  6/28          4/28
   Anticonvulsant                                 5/29          1/31
  Clinical and demographic variables (mean, SD)                 
   Gender (m/f)                                   19/15         17/15
   Melancholic (yes/no)                           19/9          12/12
   MDD/BP1/BP2                                    30/3/1        30/0/2
   Age (years)                                    48.8 (12.3)   47.5 (12.0)
   Age at onset (years)                           27.0 (9.6)    27.5 (9.6)
   Duration of current episode (months)           24.4 (32.2)   37.2 (48.0)
   Duration of previous episodes (months)         65.9 (65.8)   88.5 (93.6)
   Antidepressants failed current episode         2.1 (1.7)     2.6 (2.9)
   Total lifetime failed antidepressants          4.0 (3.0)     5.0 (5.1)
   Maudsley staging score                         7.3 (2.1)     6.5 (1.9)
   Baseline MADRS score                           29.5 (4.6)    30.1 (5.0)
   Baseline BDI-II score                          33.8 (9.1)    34.1 (9.4)
   Baseline CGI-S score                           4.4 (0.6)     4.4 (0.6)
   Baseline Q-LES-SF score                        32.8 (10.5)   34.9 (11.2)
   Baseline TEQ score                             24.5 (7.6)    24.1 (7.1)

Abbreviations: BP1/BP2, bipolar I and bipolar II disorder; BDI-II, Beck Depression Inventory; CGI-S, Clinician Global Impression Severity scale, a 7-point clinician-rated scale ranked from 1-normal to 7-extremely ill; MADRS, Montgomery-Asberg Depression Rating Scale; MDD, major depressive disorder; Q-LES-SF, Quality of Life Enjoyment and Satisfaction Questionnaire---Short Form; TEQ, Treatment Expectancy Questionnaire.

^*a*^Participants were required to cease benzodiazepine medication use prior to commencing the trial.

Clinical Outcome Measures {#s12}
-------------------------

[Table 2](#T2){ref-type="table"} shows the results for all MERM analyses of mood and quality-of-life outcome measures during the sham-controlled phase using per-protocol and intention-to-treat approaches in accordance with CONSORT guidelines for parallel group randomized control trials ([@CIT0070]). MERM analysis of MADRS scores showed a significant effect of time (*P* \< .001). There was, however, no effect of tRNS condition (*P* = .630) and no significant time × condition interaction (*P* = .445; see [Figure 1](#F1){ref-type="fig"}). Repeating the analysis while incorporating scores from the Treatment Expectations Questionnaire as an additional covariate did not modify outcomes. Concurrent medications did not significantly affect outcomes when entered as covariates in separate MERM analyses (see [supplementary Table 2](#sup1){ref-type="supplementary-material"}). [Supplementary Table 3](#sup1){ref-type="supplementary-material"} shows results from MERM analyses of all outcome measures acquired during the acute daily treatment phases combined (i.e., both sham-controlled and open-label phases). [Supplementary Figure 4](#sup1){ref-type="supplementary-material"} shows graphs of mood and quality-of-life measures for all time-points up to the 9-month follow-up assessment.

###### 

Mood and quality-of-life outcome measures

                                Baseline                          Week 2                            Week 4                            Condition          Time                 Time × Condition   
  ----------------------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------- ------ ------- ------------ ------------------ ------
  Per-protocol analysis                                                                                                                                                                          
  MADRS                         29.1 (33, 0.8)   28.9 (32, 0.8)   24.4 (33, 1.0)   24.8 (32, 1.1)   22.1 (34, 1.2)   23.7 (32, 1.3)   0.24        .630   41.73   **\<.001**   0.82               .445
  BDI-II                        32.6 (31, 1.7)   33.2 (28, 1.8)   25.2 (34, 1.9)   27.2 (32, 2.0)   22.1 (32, 1.9)   24.9 (31, 2.0)   0.72        .399   24.56   **\<.001**   0.46               .762
  CGI-I                         --               --               3.5 (33, 0.1)    3.6 (32, 0.1)    3.1 (33, 0.1)    3.4 (32, 0.1)    2.24        .140   12.69   **\<.001**   2.10               .153
  Q-LES-SF                      32.4 (34, 1.9)   36.0 (30, 2.1)   --               --               43.5 (32, 2.8)   43.9 (31, 2.9)   0.45        .503   31.67   **\<.001**   0.84               .362
  Intention-to-treat analysis                                                                                                                                                                    
  MADRS                         29.1 (34, 0.8)   29.0 (34, 0.8)   24.4 (33, 1.0)   24.8 (34, 1.1)   22.1 (34, 1.2)   23.7 (32 1.3)    0.29        .593   43.09   **\<.001**   0.77               .467
  BDI-II                        32.4 (32, 1.6)   33.4 (30, 1.7)   24.9 (34, 1.9)   27.1 (34, 2.0)   21.9 (32, 1.9)   25.1 (31, 2.0)   1.07        .306   25.07   **\<.001**   0.58               .678
  CGI-I                         --               --               3.5 (33, 0.1)    3.6 (34, 0.1)    3.1 (33, 0.1)    3.4 (32, 0.1)    2.60        .112   13.07   **\<.001**   1.98               .165
  Q-LES-SF                      32.5 (35, 1.8)   35.8 (32, 2.0)   --               --               43.6 (32, 2.8)   43.8 (31, 2.9)   0.37        .545   32.00   **\<.001**   0.80               .376

Abbreviations: BDI-II, Beck Depression Inventory; CGI-I, Clinician Global Impression Improvement scale, a 7-point clinician-rated scale ranked from 1-very much improved to 7-very much worse; MADRS, Montgomery-Asberg Depression Rating Scale; MERM, mixed-effects repeated measures; Q-LES-SF, Quality of Life Enjoyment and Satisfaction Questionnaire---Short Form.

Estimated marginal means and results from MERM analyses during the sham-controlled phase. MERM analyses were performed including the following covariates: Maudsley staging method total score as a measure of treatment resistance, and antidepressant use. Statistically significant P values (\< .05) are highlighted in bold.

![Mood scores. Graph showing Montgomery-Asberg Depression Rating Scale (MADRS) scores (estimated marginal means ± SD) across rating time points, including the sham-controlled phase (from baseline to 4 weeks), open-label phase (from 4--8 weeks), and 1-month follow-up assessment following the final taper session. Dotted lines indicate sham transcranial random noise stimulation (tRNS) sessions delivered during the sham-controlled phase.](pyz072f0001){#F1}

One participant in the active tRNS group (3.1%) and 5 participants receiving sham tRNS (14.7%) were considered treatment responders after completion of the sham-controlled phase (i.e., following 20 sessions of tRNS). Only 2 participants met the remission criterion, both in the sham tRNS condition (5.9%). Fisher's exact tests revealed no statistically significant differences between active and sham tRNS conditions for response (*P* = .198) and remission (*P* = .493) rates.

Neuroplasticity Outcome Measures {#s13}
--------------------------------

A total of 44 participants (sham: 25; active: 19) completed the optional PAS study to assess changes in motor cortical excitability. A MERM analysis found no significant effects of time (*P* = .209) or condition (*P* = .780) and no significant time × condition interaction (*P* = .570; see [Table 3](#T3){ref-type="table"} and [supplementary Figure 5](#sup1){ref-type="supplementary-material"}). Furthermore, change in MADRS scores did not correlate with changes in motor evoked potential amplitudes from baseline to the end of the sham-controlled phase (r = −0.02, *P* = .905; [supplementary Figure 6](#sup1){ref-type="supplementary-material"}). Results from intention-to-treat analyses are also reported in [supplementary Table 4](#sup1){ref-type="supplementary-material"}.

###### 

Neuroplasticity and neuropsychological outcome measures

                                                   Baseline                     Week 4                        Condition                Time          Time × Condition   
  ------------------------------------------------ -------------- ------------- -------------- -------------- ----------- ------------ ------ ------ ------------------ ------
  Neuroplasticity assessment (m, SEM)                                                                                                                                   
  PAS: MEP amplitude                               1.24 (0.10)    1.21 (0.12)   1.31 (0.09)    1.40 (0.10)    0.08        .780         1.63   .209   0.33               .570
  Neuropsychological assessments (m, SEM)                                                                                                                               
  CVLT-II: trial 1--5 total recall t-score         45.7 (2.8)     48.7 (2.2)    46.3 (2.3)     49.7 (2.2)     2.12        .148         0.12   .734   0.01               .913
  CVLT-II: long delay free recall z-score          −0.41 (0.21)   0.03 (0.22)   −0.64 (0.22)   −0.38 (0.21)   2.69        .104         1.85   .176   0.20               .653
  D-KEFS: letter fluency scaled score              11.2 (0.7)     11.5 (0.7)    10.9 (0.7)     11.9 (0.7)     0.97        .327         0.01   .945   0.32               .575
  D-KEFS: category fluency scaled score            10.3 (0.8)     10.9 (0.8)    9.8 (0.8)      11.8 (0.8)     2.84        .094         0.05   .828   0.80               .372
  D-KEFS: category switching total scaled score    10.0 (0.6)     11.1 (0.6)    9.6 (0.6)      10.6 (0.6)     3.36        .069         0.50   .480   0.02               .888
  Ruff 2 and 7: total speed t-score                47.4 (1.9)     49.9 (1.9)    51.3 (1.9)     53.6 (1.8)     1.66        .200         3.45   .066   0.01               .946
  Ruff 2 and 7: total accuracy t-score             49.6 (2.3)     46.6 (2.4)    50.4 (2.4)     48.7 (2.3)     1.02        .316         0.34   .561   0.08               .779
  SDMT: total correct z-score                      −0.31 (0.18)   0.25 (0.18)   −0.02 (0.19)   0.41 (0.18)    7.78        **.006**     1.32   .254   0.15               .703
  WAIS-IV Digit Span: total correct scaled score   9.7 (0.5)      11.5 (0.6)    10.5 (0.6)     12.6 (0.5)     13.00       **\<.001**   2.57   .112   0.12               .732
  CFQ: total score                                 50.0 (2.2)     46.8 (2.3)    49.9 (2.3)     50.0 (2.2)     0.52        .474         0.40   .528   0.57               .451

Abbreviations: CFQ, Cognitive Failures Questionnaire; CVLT, California Verbal Learning Test; D-KEFS, Delis-Kaplan Executive Function System; MEP, motor evoked potential; MERM, mixed-effects repeated measures; PAS, paired associative stimulation; SDMT, Symbol Digit Modalities Test; WAIS, Wechsler Adult Intelligence Scale.

Estimated marginal means and results from MERM analyses during the sham-controlled phase. The neuroplasticity MERM analysis were performed including the following covariates: Maudsley staging parameters total score as a measure of treatment resistance, and antidepressant use. Neuropsychological MERM analyses were performed using MADRS scores as a covariate. Statistically significant P values (\< .05) are highlighted in bold.

Neuropsychological Outcomes {#s14}
---------------------------

Neuropsychological outcomes during the sham-controlled phase are shown in [Table 3](#T3){ref-type="table"}. There were no significant main effects of time and no significant time × condition interaction effects for all neuropsychological measures. Results from intention-to-treat analyses are also reported in [supplementary Table 4](#sup1){ref-type="supplementary-material"}.

Acute Cognitive Effects {#s15}
-----------------------

For reaction time, the main effects of time (*P* = .404), condition (*P* = .992), and the time × condition interaction effect (*P* = .949) were not statistically significant. Further, for the emotion recognition task, the main effect of tRNS condition was not statistically significant (*P* = .347).

Physical Adverse Events {#s16}
-----------------------

Adverse events occurring during the sham-controlled and open-label phases of the trial are presented in [Table 4](#T4){ref-type="table"}. Side-effects were transient and mild to moderate in severity. Pearson chi-square tests revealed significantly more instances of erythema (skin redness; *P* \< .001), paresthesia (tingling, burning, and itching sensations; *P* \< .001), fatigue (*P* = .006), and dizziness/light-headedness (*P* = .002) following active tRNS compared with sham tRNS sessions.

###### 

Physical adverse event frequency

                               Sham-controlled phase                                             Open-label phase   
  ---------------------------- ----------------------- ------ ----- ------ -------- ------------ ------------------ ------
  Erythema                     129                     20.0   454   69.8   323.67   **\<.001**   781                67.3
  Tingling                     126                     19.5   332   51.1   139.96   **\<.001**   623                53.7
  Burning                      15                      2.3    251   38.6   214.14   **\<.001**   370                31.9
  Itching                      40                      6.2    97    14.9   25.21    **\<.001**   170                14.6
  Fatigue                      33                      5.1    60    9.2    7.66     **.006**     75                 6.5
  Headache                     43                      6.7    30    4.6    2.17     .141         31                 2.7
  Dizziness/light-headedness   10                      1.5    31    4.8    9.95     **.002**     48                 4.1
  Nausea                       7                       1.1    15    2.3    2.22     .136         36                 3.1
  Scalp Discomfort             7                       1.1    9     1.4    0.06     .811         10                 0.9
  Other                        14                      2.2    26    4.0    3.05     .081         58                 5.0

Adverse events are sorted according to overall likelihood of occurrence, with events most likely to occur listed first. Differences in frequency of adverse event occurrence during the sham-controlled phase was tested using Pearson chi-square tests with Yates' continuity correction. Statistically significant P values (\< .05) are highlighted in bold.

Blinding Integrity {#s17}
------------------

Participants were asked to guess their treatment condition at the end of the double-blinded sham-controlled phase. A total of 75% of participants in the sham condition correctly guessed they received sham tRNS, and 55% of participants in the active condition correctly guessed they had received active tRNS. A Pearson chi-square test of participant guesses was significant (χ ^2^ = 4.68; *P* = .031), suggesting that participants were not adequately blinded to their treatment condition. To determine whether participant guesses of treatment condition may have influenced mood outcomes, we performed a post-hoc simple linear regression analysis; percent change in MADRS score over the 4-week sham-controlled phase was selected as the dependent variable and participant guess (active, sham) as the independent variable. This analysis was not statistically significant (R^2^ = 0.023, F = 1.43, *P* = .237).

Blinded study raters were similarly asked to guess participants' treatment condition at the end of the sham-controlled phase. Raters correctly guessed that participants had received sham tRNS 56% of the time and active tRNS 31% of the time. A Pearson chi-square test found this difference not to be statistically significant (χ ^2^ = 0.492; *P* = .483). Furthermore, Cohen's kappa showed no agreement between participant and rater guesses (κ = 0.134; *P* = .329).

Discussion {#s18}
==========

Here we report the results of the first randomized control trial to examine the efficacy of tRNS for the treatment of depression. Although there was a significant reduction of depressive symptoms over the duration of the study period, there was no difference in the rate of improvement between sham and active tRNS conditions. Further, there was no significant effect of tRNS on neuroplasticity measures in the subset of participants that completed the PAS paradigm, suggesting that stimulation did not increase global cortical excitability. tRNS was found to be safe with no adverse acute cognitive, neuropsychological, or severe physical side effects. However, tRNS resulted in a higher incidence rate of skin redness (erythema) and paresthesia (tingling, itching, and burning sensations) in the active condition as well as fatigue and dizziness/light-headedness, which occurred in fewer than 10% of sessions. Nevertheless, the stimulation protocol was well tolerated with only 1 participant dropping out due to adverse effects, which were not conclusively associated with tRNS.

The results of this study do not support the use of tRNS with the current stimulation parameters as a therapeutic intervention for the treatment of depression. Despite encouraging initial evidence of significant reductions in depression scores in patients with fibromyalgia ([@CIT0017]) and a case report of improvement in MDD ([@CIT0015]), mood and quality-of-life outcomes in the active tRNS group did not differ from the placebo-controlled response in the sham group at all time points. The size of reductions in depressive symptoms observed in both conditions of the present study is broadly similar to the sham condition of previous trials of tDCS for depression ([@CIT0006]; [@CIT0039]; [@CIT0054]; [@CIT0009]; [@CIT0004]; [@CIT0068]). Of these previous tDCS trials, our study design was most similar to a recent international multisite investigation conducted by our group, which observed improvements in depression scores of 27.8% and 22.3% in sham and active tDCS conditions, respectively, compared with 24.1% and 18.0% in sham and active tRNS conditions ([@CIT0040]). We recruited participants using analogous inclusion/exclusion criteria, participant demographic and clinical characteristics, and adopted comparable stimulation parameters, at least in terms of treatment duration (30 minutes), session number and frequency (20 daily weekday sessions), and direct current intensity (2-mA direct current offset in the present study vs a marginally stronger current intensity of 2.5 mA in the tDCS study). Interestingly, the present tRNS trial and [@CIT0040] have used the highest total number of sessions and strongest stimulation parameters, including current intensity, compared with other investigations of the antidepressant effects of transcranial electrical stimulation ([@CIT0006]; [@CIT0039]; [@CIT0054]; [@CIT0009]; [@CIT0004]), with both studies reporting no advantage of active stimulation over sham. Overall, studies show tDCS has antidepressant efficacy ([@CIT0049]), though 1 study suggested this may be less than escitalopram ([@CIT0012]).

Another possible explanation for null findings in the present study is that the sample was too severely ill to respond to tRNS treatment. On average, participants had failed 4--5 antidepressants and depression scores just below the cut-off for severe depression (MADRS \> 34; see [Table 1](#T1){ref-type="table"}). Research suggests that participants with treatment-resistant depression do not respond as well to transcranial electrical stimulation such as tDCS ([@CIT0006]; [@CIT0054]; [@CIT0004]).

The synaptic plasticity hypothesis of depression purports that MDD is characterized by a partial reduction in long-term potentiation-like processes ([@CIT0059]; [@CIT0036]), suggesting that impaired synaptic plasticity, particularly in the prefrontal cortex, is a key feature of the pathophysiology of depression ([@CIT0026]; [@CIT0020]; [@CIT0053]). This hypothesis is supported by evidence that the therapeutic efficacy of antidepressants is, at least partly, due to their capacity to increase neural plasticity ([@CIT0069]; [@CIT0013]). Similarly, prior work from our group has demonstrated that a course of tDCS increases neuroplasticity and mood outcomes in depression. However, a correlation between these measures could not be confirmed due to the limited sample size (n = 18) ([@CIT0060]). Despite a larger sample size from which to detect small effects of the intervention, we did not see an increase in neuroplasticity levels following tRNS. Previous research has shown that tRNS can induce acute neuroplastic after-effects, measured by investigating changes to motor cortex excitability using transcranial magnetic stimulation motor-evoked potentials ([@CIT0076]; [@CIT0014]; [@CIT0032]). However, there is no evidence to date to suggest cumulative changes in neuroplasticity following a course of multiple repeated sessions of tRNS, as assessed in this study. An important caveat to our results is that only a subset of participants (44/69) completed the PAS study. It is theoretically possible that the subset of participants who underwent the PAS protocol had different clinical, physiological, or behavioral characteristics (e.g., greater levels of motivation) and may thus not be representative of the larger sample.

The exact purported mechanisms of action for prolonged cortical excitation following tRNS are unclear but may include either (1) temporal summation of neural activity when random noise stimuli and ongoing endogenous neuronal activity occur in close succession ([@CIT0023]), and/or (2) enhancement of neuronal signaling via the principle of stochastic resonance ([@CIT0080]). The latter refers to signals that are too weak to exceed a threshold being amplified by adding a random noise stimulus, improving the signal-to-noise ratio and the synchronization and coherence of neuronal networks ([@CIT0048]; [@CIT0056]). Though more research is required to determine which of these mechanisms dominates, the action of tRNS appears to rely heavily on detection and propagation of weak ongoing endogenous neuronal signals. The notion of stochastic resonance has been demonstrated in several tRNS experiments aimed at enhancing sensitivity to sensory inputs, including visual, auditory, and tactile stimuli ([@CIT0080]). Interestingly, investigations of auditory ([@CIT0062]) and visual ([@CIT0079]) perceptual thresholds have shown that tRNS has its largest effect on near-threshold stimuli, whereas stimuli clearly above and below threshold were unaffected. It may be for this reason that the only positive randomized control trials using tRNS in clinical populations have stimulated the sensory and motor cortices, specifically in the treatment of tinnitus via the auditory cortex ([@CIT0081]) or stimulation of the motor cortex for chronic pain in fibromyalgia ([@CIT0017]). tRNS may restore the dysfunctional activity in these cortical structures by normalizing their capacity to filter weak signals amid background neural noise. In complex disorders such as depression, however, it is unclear what the depressed "signal" might be. Studies seeking to use tRNS for other complex disorders by stimulating prefrontal cortical regions have also reported negative findings (i.e., for the treatment of multiple sclerosis; [@CIT0055]) and vegetative state ([@CIT0042]). Similarly to depression, these illnesses do not consist of a well-defined neural signal whose signaling properties can be augmented by tRNS to revert pathophysiological dysfunctions of brain activity.

Although the present study reports null findings for the use of tRNS in depression, it provides valuable information regarding the safety and tolerability of multiple repeated sessions of tRNS. To the best of our knowledge, the previous longest delivery of tRNS was 15 sessions ([@CIT0015]), whereas participants in the current study experienced up to 40 sessions over 8 weeks if allocated to the active tRNS condition. Adverse events of erythema and paresthesia were reported more frequently in the active tRNS condition compared with sham. These results are comparable with those observed in the tDCS literature, in which meta-analyses similarly suggest a greater frequency of erythema and paresthesia ([@CIT0044]; [@CIT0050]). Of interest, fatigue and dizziness/light-headedness were also noted more frequently during active tRNS sessions. These side effects are not a common adverse effect of tDCS and might be unique to the tRNS stimulation parameters used in the current study, for example, due to the current intensity ranging as high as 3 mA (2-mA direct offset with ±1-mA amplitude fluctuation). Importantly, fatigue and dizziness/light-headedness occurred rarely in only 9.2% of sessions for fatigue and 4.8% for light-headedness. Additionally, these adverse events were transient, resolved on their own shortly after cessation of stimulation, and were not reported to be severe in intensity.

A limitation of the present study is that blinding was not preserved, possibly due to the increased incidence of adverse events during active tRNS compared to sham. One would expect inadequate blinding to reduce placebo effects for participants in the sham condition and potentially enhance them for participants receiving active tRNS, thereby increasing the likelihood of observing a difference between groups. This was not the case in the present study. Indeed, scores for mood outcomes were quantitatively (but not significantly) better in the sham condition compared with active tRNS, suggesting that inadequate blinding did not bias results in favor of the active treatment. Future studies may consider alternative methods to adequately blind participants, including the use of a topical salve beneath the site of stimulation to reduce paresthetic effects and erythema ([@CIT0043]; [@CIT0027]) or comparisons against an active control condition ([@CIT0024]).

A major strength of the present study is the research design, which included double blinding of participants and raters, examination of mood outcomes in addition to neuroplasticity changes, comprehensive assessment of adverse events using neuropsychological and physical measures, reporting of long-term follow-up outcomes up to 9 months following completion of the open-label phase, and rigorous statistical analysis methodology informed by CONSORT guidelines.

Conclusion {#s19}
==========

This study represents, to our knowledge, the first randomized control trial for the use of tRNS to treat depression. Our findings do not lend support for the use of tRNS as a therapeutic intervention for depression. Antidepressant response was similar between active and sham tRNS conditions. tRNS did not increase motor cortical excitability, a measure of neuroplasticity associated with antidepressant response in other successful therapeutic clinical trials of depression ([@CIT0069]; [@CIT0013]). The profile of adverse events for tRNS was similar to that of tDCS, with a significantly greater likelihood of erythema and paresthesia in the active tRNS condition, in addition to a higher incidence rate of fatigue and dizziness/light-headedness. Participant blinding was not preserved and may be related to the increased frequency of side effects in the active condition. Overall, the treatment was well tolerated by participants.
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